{
    "ticker": "SLRX",
    "name": "Salarius Pharmaceuticals, Inc.",
    "description": "Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cancer. Founded in 2016 and based in Houston, Texas, Salarius focuses on developing drugs that target the underlying mechanisms of cancer, particularly those that affect the epigenetic landscape of tumors. Its lead product candidate, EP0042, is a potent, orally available small molecule that inhibits specific proteins involved in cancer cell proliferation and survival. The company is committed to addressing unmet medical needs in oncology by advancing its drug candidates through clinical trials and ultimately to market. Salarius collaborates with leading academic and clinical institutions to enhance its research and development efforts, with the goal of transforming the lives of patients facing serious health challenges. The company's mission is driven by a passion for science and a commitment to improving patient outcomes through innovative treatments and therapies.",
    "industry": [
        "Biopharmaceuticals",
        "Oncology"
    ],
    "headquarters": "Houston, Texas, USA",
    "founded": "2016",
    "website": "https://www.salariuspharma.com",
    "ceo": "David Arthur",
    "social_media": {
        "twitter": "https://twitter.com/SalariusPharma",
        "linkedin": "https://www.linkedin.com/company/salarius-pharmaceuticals-inc/"
    },
    "investor_relations": "https://www.salariuspharma.com/investor-relations",
    "key_executives": [
        {
            "name": "David Arthur",
            "position": "CEO"
        },
        {
            "name": "Ravi K. R. P. S. S. M. P. T. V. K. Reddy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Development Stage Products",
            "products": [
                "EP0042"
            ]
        }
    ],
    "seo": {
        "meta_title": "Salarius Pharmaceuticals, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing epigenetic therapies for cancer patients. Learn about our innovative treatments and commitment to patient care.",
        "keywords": [
            "Salarius Pharmaceuticals",
            "Cancer Therapy",
            "Biopharmaceuticals",
            "EP0042",
            "Oncology",
            "Clinical Stage"
        ]
    },
    "faq": [
        {
            "question": "What does Salarius Pharmaceuticals focus on?",
            "answer": "Salarius Pharmaceuticals focuses on developing innovative therapies for cancer patients, particularly those targeting epigenetic mechanisms."
        },
        {
            "question": "Where is Salarius Pharmaceuticals headquartered?",
            "answer": "Salarius Pharmaceuticals is headquartered in Houston, Texas, USA."
        },
        {
            "question": "What is Salarius Pharmaceuticals' lead product candidate?",
            "answer": "Salarius' lead product candidate is EP0042, aimed at targeting cancer cell proliferation."
        },
        {
            "question": "When was Salarius Pharmaceuticals founded?",
            "answer": "Salarius Pharmaceuticals was founded in 2016."
        }
    ],
    "competitors": [
        "CLVS",
        "MDGL",
        "TGTX",
        "NERV"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "VRTX"
    ]
}